HK1120424A1 - Carbazole derivatives as functional 5-ht6 ligands - Google Patents

Carbazole derivatives as functional 5-ht6 ligands

Info

Publication number
HK1120424A1
HK1120424A1 HK08113183.2A HK08113183A HK1120424A1 HK 1120424 A1 HK1120424 A1 HK 1120424A1 HK 08113183 A HK08113183 A HK 08113183A HK 1120424 A1 HK1120424 A1 HK 1120424A1
Authority
HK
Hong Kong
Prior art keywords
carbazole derivatives
receptor
ligands
functional
stereoisomers
Prior art date
Application number
HK08113183.2A
Other languages
English (en)
Inventor
Venkata Satya Nirogi Ramakrishna
Rama Sastri Kambhampati
Vikas Shreekrishna Shirsath
Jagadish Babu Konda
Santosh Vishwakarma
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of HK1120424A1 publication Critical patent/HK1120424A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Indole Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Photoreceptors In Electrophotography (AREA)
HK08113183.2A 2005-10-19 2008-12-03 Carbazole derivatives as functional 5-ht6 ligands HK1120424A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1504CH2005 2005-10-19
PCT/IN2006/000195 WO2007046111A1 (en) 2005-10-19 2006-06-09 Carbazole derivatives as functional 5-ht6 ligands

Publications (1)

Publication Number Publication Date
HK1120424A1 true HK1120424A1 (en) 2009-04-03

Family

ID=37054637

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113183.2A HK1120424A1 (en) 2005-10-19 2008-12-03 Carbazole derivatives as functional 5-ht6 ligands

Country Status (24)

Country Link
US (1) US8143303B2 (pt)
EP (1) EP1948166B1 (pt)
JP (1) JP2009512681A (pt)
KR (1) KR101125820B1 (pt)
CN (1) CN101291670B (pt)
AT (1) ATE485040T1 (pt)
AU (1) AU2006305502B2 (pt)
BR (1) BRPI0619308A2 (pt)
CA (1) CA2626646C (pt)
CY (1) CY1111560T1 (pt)
DE (1) DE602006017722D1 (pt)
DK (1) DK1948166T3 (pt)
EA (1) EA014694B1 (pt)
ES (1) ES2354455T3 (pt)
HK (1) HK1120424A1 (pt)
HR (1) HRP20110041T1 (pt)
NO (1) NO341252B1 (pt)
NZ (1) NZ567865A (pt)
PL (1) PL1948166T3 (pt)
PT (1) PT1948166E (pt)
RS (1) RS51627B (pt)
SI (1) SI1948166T1 (pt)
WO (1) WO2007046111A1 (pt)
ZA (1) ZA200803118B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055386A2 (en) * 2011-10-03 2013-04-18 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
CN106045972B (zh) * 2016-06-03 2018-11-16 中山大学 咔唑-利凡斯的明二联体及其药物组合物和应用
CN106749184B (zh) * 2016-11-15 2020-07-17 中山大学 8-氨基喹啉-羟基咔唑杂联体，其制备方法及其药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1149078T3 (da) * 1998-12-11 2006-07-10 Univ Virginia Commonwealth Selektive 5-HT6-receptorligander
JP2005508349A (ja) * 2001-10-09 2005-03-31 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー ５−ｈｔ６受容体リガンドとしてのアリールスルホニル置換されたテトラヒドロ−およびヘキサヒドロ−カルバゾール

Also Published As

Publication number Publication date
NO20081739L (no) 2008-07-09
CA2626646C (en) 2011-03-01
CA2626646A1 (en) 2007-04-26
HRP20110041T1 (hr) 2011-02-28
ZA200803118B (en) 2011-11-30
NO341252B1 (no) 2017-09-25
CN101291670B (zh) 2012-07-04
EA200801114A1 (ru) 2009-02-27
EA014694B1 (ru) 2010-12-30
ATE485040T1 (de) 2010-11-15
EP1948166B1 (en) 2010-10-20
SI1948166T1 (sl) 2011-02-28
NZ567865A (en) 2010-07-30
KR101125820B1 (ko) 2012-03-28
PT1948166E (pt) 2011-01-19
AU2006305502A1 (en) 2007-04-26
BRPI0619308A2 (pt) 2013-03-05
AU2006305502B2 (en) 2009-11-26
RS51627B (en) 2011-08-31
CN101291670A (zh) 2008-10-22
DE602006017722D1 (de) 2010-12-02
CY1111560T1 (el) 2015-10-07
DK1948166T3 (da) 2011-01-31
EP1948166A1 (en) 2008-07-30
US8143303B2 (en) 2012-03-27
JP2009512681A (ja) 2009-03-26
US20100189646A1 (en) 2010-07-29
KR20080064848A (ko) 2008-07-09
PL1948166T3 (pl) 2011-04-29
WO2007046111A1 (en) 2007-04-26
ES2354455T3 (es) 2011-03-15

Similar Documents

Publication Publication Date Title
PL1888541T3 (pl) Związki benzo[d]izoksazol-3-iloaminy i ich zastosowanie jako ligandów receptora waniloidowego
WO2006132914A3 (en) Cyclobutyl amine derivatives
IL190654A (en) Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them
GB0510141D0 (en) Novel compounds B3
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
TW200740814A (en) Compounds
PT1877367E (pt) Derivados do acetileno
HK1116796A1 (en) Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2007150010A3 (en) Cyclopropyl amine derivatives as histamin h3 receptor modulators
WO2007021711A3 (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
DK2155674T3 (da) Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander
HK1120424A1 (en) Carbazole derivatives as functional 5-ht6 ligands
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
TW200633987A (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
WO2005097757A3 (en) Nucleoside derivatives and therapeutic use thereof
WO2007109871A3 (en) Acridine derivatives with antitumoral activity
WO2007079929A3 (de) Substituierte tricyclische piperidon-derivate

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200605